Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing
Ohio State University Comprehensive Cancer Center
Summary
Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing
Description
This study supports the collection of tumor specimens for CLIA-certified genomic testing and research testing in parallel. CLIA-certified tests have established measurements of accuracy and precision which allow for return of results. This study does not involve treatment, only testing, which could be used to meet eligibility criteria in other trials or therapies. This study includes a registry for longitudinal evaluation of patients whose cancer has FGFR mutations such as cholangiocarcinoma, pancreatic cancer, and others (telehealth).
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. A histologically or cytologically confirmed diagnosis of cancer 2. Patients with any malignancy. 3. Patients must have tumor suitable for research tumor biopsy (as assessed by trained specialists in interventional radiology) and Patients are medically fit to undergo a tissue biopsy or surgical procedure to get tumor tissue OR If Patients do not have a tumor suitable for biopsy but have another tissue available for molecular evaluation. OR Patients are undergoing standard of care surgeries or procedures where fresh specimens will be first used for routine pathologic…
Interventions
- OtherBiospecimen collection
Specimens to be collected include a fresh tumor biopsy, previously obtained tumor specimens or blocks (if available), whole blood, serum, plasma and buccal smear.
Location
- Ohio State University Wexner Medical CenterColumbus, Ohio